Sacituzumab govitecan
拓达维(Trodelvy)
A Trop-2 antibody-drug conjugate for aggressive breast cancers.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
NRDL status pending verification.
Regulatory status
NMPA approved (2023); NRDL
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Triple-negative breast cancer after 2+ prior therapies; HR+/HER2- breast cancer.
How it is accessed in China
- /DTP
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Sacituzumab govitecan. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.